MINNEAPOLIS—Medtronic Diabetes announced the expansion of United States pharmacy formulary access for its MiniMed 780G insulin pump, through agreements with major pharmacy benefit managers (PBMs) and PBM group purchasing organizations (GPOs), including Ascent and Zinc. These agreements also include access to Medtronic Diabetes’ expanded CGM portfolio—Simplera sensor, Simplera Sync sensor and Instinct sensor, made by Abbott—and build on existing pharmacy coverage for Medtronic CGMs and consumables, such as infusion sets and reservoirs.
“Expanding pharmacy benefit coverage for the MiniMed 780G system is an important step forward in how people access automated insulin delivery,” said Que Dallara, executive vice president & president of Medtronic Diabetes. “Access through the pharmacy channel can help lower upfront costs compared to traditional durable medical equipment (DME) pathways and make it easier for people to get started on therapy. It also allows patients and care teams to better align pumps, sensors, and consumables under a single coverage pathway, supporting greater predictability when navigating access.”
Providers can prescribe the MiniMed 780G system, and Medtronic Diabetes will continue to manage benefit investigation across both pharmacy and DME options. This company said this approach aims to provide transparency into available coverage pathways and helps customers choose the options that best meets their needs.